comparemela.com

Latest Breaking News On - குழந்தை பருவம் புற்றுநோய் - Page 27 : comparemela.com

Projects & Studies

Projects & Studies Description The Acute Effects of Exercise on Breast Cancer Biomarkers (ACE Study) is enrolling women to test the effect of moderate intensity exercise on cancer risk factors such as biomarkers in healthy women. Knowing if exercise significantly alters these biomarkers, could help support guidelines for daily exercise for breast cancer prevention and could indicate that exercise even without weight loss is beneficial. Advanced Colorectal Cancer of Serrated Subtype (ACCESS) Study Description Funding Agency: National Institutes of Health Advancing our Understanding of the Etiologies and Mutational Landscapes of Basal-like, Luminal A, and Luminal B Breast Cancer Description Addressing research gaps in the molecular subtypes of breast cancer, we are taking a multidisciplinary approach to study the epidemiology and mutational landscapes of basal-like, luminal A, and luminal B tumors.

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

Press release content from PR Newswire. The AP news staff was not involved in its creation. OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4 April 6, 2021 GMT TAIPEI, Taiwan, April 6, 2021 /PRNewswire/ OBI Pharma, Inc. (TPEx: 4174) today announced the data highlighting the characteristics and antitumor efficacy of OBI-3424 and animal studies of OBI-998, as well as the T-cell inhibitory roles of Globo-H and SSEA-4 in the tumor microenvironment, will be presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting from April 10–15, 2021. OBI’s Chief Scientific Officer, Ming-Tain Lai, Ph. D stated that “OBI Pharma is proud to present at the AACR Annual Meeting our latest findings on our Cancer portfolio products, OBI-3424 and OBI-998. OBI-3424′s impressive anti-AKR1C3 tumor activities in various cancer models, and enhanced efficacy when used in combination with standard-of-care chemothe

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.